EQUILLIUM, INC. Foreign Currency Transaction Gain (Loss), Unrealized
EQUILLIUM, INC. (EQ) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$53.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-13
- EQUILLIUM, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was -$46.00K, a 112.43% decline year-over-year.
- EQUILLIUM, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$7.00K, a 114.29% decline year-over-year.
- EQUILLIUM, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was -$57.00K.
- EQUILLIUM, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was $112.00K, a 67.25% decline year-over-year.
- EQUILLIUM, INC. foreign currency transaction gain (loss), unrealized for fiscal 2025 was $474.00K.
- EQUILLIUM, INC. foreign currency transaction gain (loss), unrealized for fiscal 2024 was -$794.00K.
- EQUILLIUM, INC. foreign currency transaction gain (loss), unrealized for fiscal 2023 was -$58.00K.
- EQUILLIUM, INC. foreign currency transaction gain (loss), unrealized for fiscal 2022 was -$260.00K.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$53.00K 10-Q · filed 2026-08-13 | -$110.00K derived: sum of 3 quarters · filed 2026-08-13 | $2.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$7.00K 10-Q · filed 2026-05-13 | -$64.00K derived: sum of 2 quarters · filed 2026-05-13 | $48.00K derived: sum of 3 quarters · filed 2026-05-13 | $418.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $55.00K derived: sum of 2 quarters · filed 2026-03-25 | $425.00K derived: sum of 3 quarters · filed 2026-08-13 | $474.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $482.00K derived: sum of 2 quarters · filed 2026-08-13 | $531.00K 10-Q · filed 2025-11-13 | -$446.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $370.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $419.00K 10-Q · filed 2026-08-13 | -$558.00K derived: sum of 3 quarters · filed 2026-08-13 | -$216.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $49.00K 10-Q · filed 2026-05-13 | -$928.00K derived: sum of 2 quarters · filed 2026-05-13 | -$586.00K derived: sum of 3 quarters · filed 2026-05-13 | -$362.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$977.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$635.00K derived: sum of 2 quarters · filed 2026-03-25 | -$411.00K derived: sum of 3 quarters · filed 2026-03-25 | -$794.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $342.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $566.00K derived: sum of 2 quarters · filed 2025-11-13 | $183.00K 10-Q · filed 2025-11-13 | $540.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$159.00K 10-Q · filed 2025-08-14 | $198.00K derived: sum of 3 quarters · filed 2025-08-14 | $53.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$383.00K 10-Q · filed 2025-05-14 | -$26.00K derived: sum of 2 quarters · filed 2025-05-14 | -$171.00K derived: sum of 3 quarters · filed 2025-05-14 | -$282.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $212.00K derived: sum of 2 quarters · filed 2025-03-27 | $101.00K derived: sum of 3 quarters · filed 2025-03-27 | -$58.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$145.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$256.00K derived: sum of 2 quarters · filed 2024-11-13 | -$415.00K 10-Q · filed 2024-11-13 | -$156.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$270.00K 10-Q · filed 2024-08-08 | -$11.00K derived: sum of 3 quarters · filed 2024-08-08 | -$311.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$159.00K 10-Q · filed 2024-05-09 | $100.00K derived: sum of 2 quarters · filed 2024-05-09 | -$200.00K derived: sum of 3 quarters · filed 2024-05-09 | -$600.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$41.00K derived: sum of 2 quarters · filed 2024-03-25 | -$441.00K derived: sum of 3 quarters · filed 2024-03-25 | -$260.00K 10-K · filed 2024-03-25 |
| 2022-09-30 | -$300.00K 10-Q · filed 2022-11-14 | -$700.00K derived: sum of 2 quarters · filed 2022-11-14 | -$519.00K 10-Q · filed 2023-11-08 | -$538.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-06-30 | -$400.00K 10-Q · filed 2022-08-15 | -$245.00K 10-Q · filed 2023-08-09 | -$238.00K derived: sum of 3 quarters · filed 2023-05-11 | -$438.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-03-31 | $140.00K 10-Q · filed 2023-05-11 | $162.00K derived: sum of 2 quarters · filed 2023-05-11 | -$38.00K derived: sum of 3 quarters · filed 2023-05-11 | -$138.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$178.00K derived: sum of 2 quarters · filed 2023-03-23 | -$278.00K derived: sum of 3 quarters · filed 2023-03-23 | -$240.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$200.00K 10-Q · filed 2022-11-14 | -$300.00K derived: sum of 2 quarters · filed 2022-11-14 | -$262.00K 10-Q · filed 2022-11-14 | -$75.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$100.00K 10-Q · filed 2022-08-15 | -$107.00K 10-Q · filed 2022-08-15 | $125.00K derived: sum of 3 quarters · filed 2022-08-15 | $244.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$50.00K 10-Q · filed 2022-05-12 | $225.00K derived: sum of 2 quarters · filed 2022-05-12 | $344.00K derived: sum of 3 quarters · filed 2022-05-12 | $646.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $394.00K derived: sum of 2 quarters · filed 2022-03-23 | $696.00K derived: sum of 3 quarters · filed 2022-03-23 | $360.00K 10-K · filed 2022-03-23 |
| 2020-09-30 | $119.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $421.00K derived: sum of 2 quarters · filed 2021-11-10 | $85.00K 10-Q · filed 2021-11-10 | $124.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $302.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$34.00K 10-Q · filed 2021-08-10 | $5.00K derived: sum of 3 quarters · filed 2021-08-10 | -$2.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$336.00K 10-Q · filed 2021-05-13 | -$297.00K derived: sum of 2 quarters · filed 2021-05-13 | -$304.00K derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $32.00K derived: sum of 2 quarters · filed 2021-03-24 | $20.00K 10-K · filed 2021-03-24 | |
| 2019-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$19.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$12.00K 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |